Psych MEQs / SAQs · Old age psychiatry — anxiety disorders
Late-life anxiety disorders — assessment and management (MEQ)
FRANZCP-style MEQ on late-life GAD: formulation, GAD-7, suicide risk, SSRI with hyponatraemia/diuretic caution, CBT evidence (Stanley), Beers benzodiazepine deprescribing.
On this page & tools
Target exams
Model answer
Reveal model answer
(i) Formulation and differentials. This is most consistent with late-life generalised anxiety disorder (multi-domain excessive worry more than 6 months, tension, insomnia, avoidance, elevated GAD-7) with functional disability and possible anxious distress short of a full major depressive episode — still screen depression carefully given passive death-related thoughts.[1][7][8] Differentials: comorbid or primary major depression; illness anxiety focus on heart disease; panic/agoraphobia spectrum given shopping avoidance; benzodiazepine-related rebound anxiety or dependence maintaining insomnia; medical mimics (arrhythmia, thyroid disease, anaemia) — baseline work-up still required even if GP “unremarkable” needs confirmation; mild cognitive impairment contributing to worry about competence.[1]
(ii) Assessment and risk. Full history of onset (early vs late), alcohol, full medication list, falls, cognition screen, collateral from daughter/GP. Structured suicide assessment: passive ideation already present — explore intent, plan, means (medications, heights), protective factors; older adults have high lethality even with fewer attempts.[6] Capacity for treatment decisions; fear-of-falling and function (IADLs). Repeat vitals, ECG if cardiac worry/symptoms, labs including sodium before SSRI because she is on a thiazide.[4]
(iii) Management plan. Psychoeducation that late-life GAD is treatable and not “normal ageing.” Offer late-life adapted CBT (worry monitoring, cognitive restructuring, relaxation, behavioural activation/exposure to avoided activities) — Stanley primary-care RCT supports CBT for older adults with GAD.[2] Pharmacotherapy: start an SSRI low and slow, e.g. sertraline 25 mg orally daily or escitalopram 5 mg orally daily, titrate cautiously toward an effective dose within older-adult product limits; Lenze RCT supports escitalopram efficacy in late-life GAD.[3] Monitor early for activation, falls, GI effects, and hyponatraemia (check sodium within 1–2 weeks and if confusion/falls occur), especially with thiazide diuretic.[4] Measurement-based care with serial GAD-7.[7] Involve PT/OT if fear of falling dominates; optimise sleep hygiene and reduce caffeine.
(iv) Benzodiazepine management. Four years of nightly diazepam is potentially inappropriate long-term therapy in older adults (AGS Beers) — discuss risks (falls, cognition, dependence) and negotiate a slow supervised taper while CBT/SSRI take effect, rather than abrupt cessation (withdrawal risk).[5] Do not increase diazepam as definitive care.
(v) Follow-up and disposition. Initially primary care collaborative follow-up with psychology referral; step up to old-age CMHT if risk escalates, depression deepens, or community supports fail. Early review after SSRI start; crisis plan for worsening suicidal thinking; carer education. Reassess cognition and function after anxiety improves.[1][6]
Common errors
- Starting long-term higher-dose benzodiazepine as the main treatment.
- Ignoring thiazide–SSRI hyponatraemia risk and failing to check sodium.
- Dismissing passive death thoughts because she “only has anxiety.”
- Claiming CBT cannot work in older adults.
- Abruptly stopping long-term diazepam without a taper plan. [2][4][5][6]
Examiner notes
Full marks require GAD formulation, suicide/means attention, named SSRI start-low plan with sodium monitoring, Stanley-style CBT, and Beers-informed benzodiazepine taper. Vague “reassure and give diazepam” fails. [2][3][5]
References
- [1]Wolitzky-Taylor KB, Castriotta N, Lenze EJ, Stanley MA, Craske MG Anxiety disorders in older adults: a comprehensive review Depress Anxiety, 2010.PMID 20099273
- [2]Stanley MA, Wilson NL, Novy DM, et al. Cognitive behavior therapy for generalized anxiety disorder among older adults in primary care: a randomized clinical trial JAMA, 2009.PMID 19351943
- [3]Lenze EJ, Rollman BL, Shear MK, et al. Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial JAMA, 2009.PMID 19155456
- [4]Fabian TJ, Amico JA, Kroboth PD, et al. Paroxetine-induced hyponatremia in older adults: a 12-week prospective study Arch Intern Med, 2004.PMID 14769630
- [5]By the 2023 American Geriatrics Society Beers Criteria Update Expert Panel American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults J Am Geriatr Soc, 2023.PMID 37139824
- [6]Conwell Y, Van Orden K, Caine ED Suicide in older adults Psychiatr Clin North Am, 2011.PMID 21536168
- [7]Spitzer RL, Kroenke K, Williams JB, Löwe B A brief measure for assessing generalized anxiety disorder: the GAD-7 Arch Intern Med, 2006.PMID 16717171
- [8]Porensky EK, Dew MA, Karp JF, et al. The burden of late-life generalized anxiety disorder: effects on disability, health-related quality of life, and healthcare utilization Am J Geriatr Psychiatry, 2009.PMID 19472438